Possible mechanisms of valproate in migraine prophylaxis

Cephalalgia

Volumn 17, Issue 2, 1997, Pages 93-100

  Cutrer, F M ^a   Limmroth, V ^a   Moskowitz, M A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID; DOPAMINE; ENKEPHALIN; EXCITATORY AMINO ACID; N METHYL DEXTRO ASPARTIC ACID; NEUROPEPTIDE; SEROTONIN; VALPROIC ACID;

4 AMINOBUTYRIC ACID BRAIN LEVEL; DRUG MECHANISM; GABAERGIC SYSTEM; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MIGRAINE; MUSCLE SPINDLE AFFERENT NERVE; NEUROTRANSMISSION; NONHUMAN; ORAL DRUG ADMINISTRATION; PROPHYLAXIS; REVIEW; TRIGEMINAL NERVE; TRIGEMINAL NUCLEUS;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; MIGRAINE DISORDERS; VALPROIC ACID;

EID: 0031001697     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1997.1702093.x     Document Type: Review

References (84)

1. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992;12:81-4
2. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-crossover study. Neurology 1994;44:647-51
3. Coria F, Sempere AP, Duarte J, Claveria LE, Cabezas C, Bayon C. Low-dose sodium valproate in the prophylaxis of migraine. Clin Neuropharmacol 1994;17:569-73
4. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52(3):281-6
5. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache: an open label study. Headache 1991;31:71-4
6. Hering R, Kurtizky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia 1989;9:195-8
7. A receptor channels. Annu Rev Neurosci 1994;17:569-602
8. B receptors. Trends Pharmacol Sci 1993;14:259-61
9. Loescher W. GABA in plasma, CSF and brain of dogs during acute and chronic treatment with gamma-acetylenic GABA and valproic acid. In: Okada Y, Roberts E, editors. Problems in GABA research. From brain to bacteria. Amsterdam: Excerpta Medica, 1982:102-9
10. Loescher W, Vetter M. In vivo effects of aminooxyacetic acid and valproic acid on nerve terminal (synapstosomal) GABA levels in discrete brain areas of the rat. Biochem Pharmacol 1985;34:1747-56
11. Loescher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol 1981;30:1364-6
12. Maitre M, Ciesielski L, Cash C, Mandel P. Comparison of the structural characteristics of the 4-aminobutyrate:2-oxyglutarate transaminases from rat and human brain, and of their affinities for certain inhibitors. Biochim Biophys Acta 1978;522:385-99
13. van der Laan JW, De Boer T, Bruinvels J. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semiadehyde dehydrogenase and indirect inhibition of GABA-transaminase. J Neurochem 1979;32:1769-80
14. Ekwuru MO, Cunningham JR. Phaclofen increases GABA release from valproate treated rats. Br J Pharmacol 1990;99 Suppl:251P
15. Kane M, Murawsky, C Rogers. Selective modulation of GABA-activated chloride currents by MDL 27192 and valproic acid. Abstract 217.11. Society for Neuroscience Meeting, Miami Beach Nov. 13-18, 1994
16. Chapman A, Keane PE, Meldrum BS, Simiand J, Verrieres JD. Mechanisms of anticonvulsant action of valproate. Progr Neurobiol 1982;19:315-59
17. 2+ uptake and amino acid neurotransmitter release in vitro. Epilepsia 1987;28:378-82
18. Zeise ML, Kasparow S, Zieglgaensberger W. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 1991; 544:345-8
19. 2+ and K+ in the hippocampal slice. Brain Res 1986;386:1-11
20. Vayer P, Cash CD, Maitre M. Is the anticonvulsant mechanism of valproate linked to its interaction with the cerebral gamma-hydroxybutyrate from gammaminobutyrate in rat brain. J Neurochem 1988;38:848-51
21. Martin-Gallard A, Rodriguez P, Lopez M, Benavides J, Ugarte M. Effects of dipropylacetate on the glycine cleavage enzyme systems and glycine levels. Biochem Pharmacol 1985;34:2877-82
22. Similae S, von Wendt L, Linna SL, Saukkonen AL, Huhtamiemi I. Dipropylacetate and hyperglycemia. Neuropaedatric 1979;1:158-60
23. Patsalos PN, Lascelles PT. Changes in regional brain levels of amino acid putative neurotransmitters after prolonged treatment with the anticonvulsant drugs diphenylhydantoin, phenobarbitone, sodium valproate, ethosuximinde, and sulthiamine in the rat. J Neurochem 1981;36:688-95
24. Whitton PS, Fowler LJ. The effect of valproic acid on 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentration in hippocampal dialysates in vivo. Eur J Pharmacol 1991;200:167-9
25. Horton RW, Anlezark GM, Sawaya MCB, Meldrum BS. Monoamine and GABA metabolism and the anticonvulsant action of di-n-propylacetate and ethanolamine-O-sulphate. Eur J Pharmacol 1977;41:387-97
26. Hwang EC, van Woert MH. Effect of valproic acid on serotonin metabolism. Neuropharmacology 1979;18:391-7
27. Biggs CS, Fowler LJ, Pearce BR, Whittom PS. The effect of sodium valproate on dopamine and 3,4-dihydroxyphenylacetic acid levels in rat hippocampal dialysates in vivo. Br J Pharmacol 1991;104:62P
28. Zimmer R, Teelken AW, Guenduerewa M, Ruether E, Cramer H. Effect of sodium valproate on CSF GABA, cAMP, cGMP and homovanillic acid levels in men. Brain Res Bull 1980;5 Suppl 2:585-8
29. Nagao T, Oshimo T, Mitsunobu K, Sato M, Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug induced tremor. Biol Psychiatr 1979;14:509-23
30. Vion-Dury J, Cupo A, Jarry T. Relations between GABAergic and enkephalinergic systems: effects of sodium valproate on rat brain enkephalins. NIDA Res Monograph 1986;75:426-9
31. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use-voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986;237:1001-11
32. Slater GE, Johnston D. Sodium valproate increases potassium conductance in Aplysia neurons. Epilepsia 1978;19:379-84
33. Perlman BJ, Goldstein DB. Membrane-disordering potency and anticonvulsant action of valproic acid and other short chain fatty acids. Mol Pharmacol 1984;26:83-9
34. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981;9:344-52
35. Woods RP, Iacoboni M, Mazziotta JC. Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. NEJM 1994;331:1689-92
36. Cutrer FM, Sorensen AG, Weisskoff RM, Ostergaard L, Rosen BR. Brain perfusion defects during spontaneous migrainous aura. 1997 (submitted)
37. Milner P. Note on a possible correspondence between the scotomas of migraine and spreading depression of Leao. EEG Clin Neurophysiol 1958;10:705
38. Lauritzen M, Olesen J. Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain 1984;107:447-61
39. Nicholson C, Kraig RP. The behavior of extracellular ions during spreading depression. In: Zeuthen T, editor. The application of ion-selective microelectrodes. Amsterdam: Elsevier/North Holland, 1981:217-38
40. Lauritzen M, Hansen AK, Kronberg D, Wieloch T. Cortical spreading depression is associated with arachadonic acid accumulation and preservation of energy charge. J Cereb Blood Flow Metab 1990;10:115-22
41. Moskowitz M, Nozaki K, Kraig R. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity with the trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 1993;13:1167-77
42. Van Hareveld A. The nature of chick's magnesium-sensitive retinal spreading depression. J Neurobiol 1984;15:333-4
43. Hansen AJ, Lauritzen M, Wieloch T. NMDA antagonists inhibit cortical spreading depression, but not axonic depolarization. In: Cavalheiro A, Lehman J, Turski L, editors, Frontiers in excitatory amino acid research. New York: Liss, 1988:661-6
44. Marrannes R, Willems R, De Prins E, Wauquier A. Evidence for a role of the N-methyl-D-aspartate (NMDA) receptor in cortical spreading depression in the rat. Brain Res 1988;457:226-40
45. Kaube H, Goadsby PJ. Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur Neurol 1994;34:30-5
46. Ray BS, Wolff HG. Experimental studies on headache. Pain-sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813
47. Kurizky A. Autonomic nervous system imbalance in migraine. Cephalalgia 1987;7 Suppl 6:539-41
48. Aubineau P, Delepine L. Plasma protain extravasation (PPE) induced in the rat dura mater by electrical stimulation of the sphenopalatine ganglion. Cephalagia 1995;15 Suppl 14:60
49. Mayberg MA, Langer RS, Zervas NT, Moskowitz MA. Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headache in man. Science 1981;213:228-30
50. Buzzi MG, Carter WB, Shimizu T, Heath H, III, Moskowitz MA. Dihydroergotamine and sumatriptan attenuates levels of CGRP in plasma in rat sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991;30:1193-200
51. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56
52. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 1987;7:4129-36
53. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 1991;44:97-112
54. Barnes PJ. Neuropeptides in human airways: function and clinical implications. Am Rev Respir Dis 1987;136:77S
55. Levine JD, Dardick SJ, Roisen MF, Helms C, Basbaum AI. Contribution of sensory afferents and sympathetic efferents to joint injury in experimental arthritis. J Neurosci 1986;6:3423
56. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993;43 Suppl 3: S16-S20
57. A receptor mediated effects of sodium valproate on dural plasma extravasation to substance P and trigeminal stimulation. Br J Pharmacol 1995; 116:1661-7
58. A receptor-mediated effects of progesterone: its ring A-metabolites and synthetic neuroactive steroids on neurogenic edema in the rat meninges. Br J Pharmacol 1996;117:99-104
59. Limmroth V, Lee WS, Cutrer FM, Waeber C, Moskowitz MA. Progesterone and its ring-A-reduced metabolites suppress dural plasma extravasation by activation of peripheral GABAA-receptors. Cephalalgia 1995;15 Suppl 14:98
60. Hunt SP, Pini A, Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 1987;328:632-4
61. Presley RW, Menetrey D, Levine JD, Basbaum AL. Systemic morphine suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in the rat spinal cord. J Neurosci 1990;10:323-35
62. Nozaki K, Boccalini P, Moskowitz MA. Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space. Neuroscience 1992;49(3):669-80
63. Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992;106:409-15
64. Cutrer FM, Limmroth V, Ayata G, Moskowitz MA. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol 1995;116:3199-204
65. Cutrer FM, Moskowitz MA. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996;36:579-85
66. Barber RP, Vaughn JE, Roberts E. The cytoarchitecture of GABAergic neurons in rat spinal cord. Brain Res 1982;238:305-28
67. Carlton SM, Hayes ES. Light microscopic and ultrastructural analysis of GABA-immunoreactive profiles in the monkey spinal cord. J Comp Neurol 1990;300:162-82
68. Magoul R, Onteniente B, Geffard M, Calas A. Anatomical distribution and ultrastructural organization of the GABAergic system in the rat spinal cord. An immunohistochemical study using anti-GABA antibodies. Neuroscience, 1987;20: 1001-9
69. Palacios JM, Wamsley JK, Kuhar MJ. High affinity GABA receptors - autoradiographic localization. Brain Res 1981; 222:285-307
70. B receptor site distribution in the rat central nervous system. Neuroscience, 1987;20:365-83
71. Waldvogel HJ, Faull RLM, Jansen KLR, Dragunow M, Richards JG, Mohler H, Strett P. GABA receptors and benzodiazepine receptors in the human spinal cord: an autoradiographic and immunohistochemical study at the light and electron microscopic levels. Neuroscience 1990;39:361-85
72. Fields HL. Pain pathways in the CNS, In: Pain. New York: McGraw-Hill, 1987:31-78
73. Giesler GJ, Gebhart KD, Yezierski RP, Wilcox TK, Willis WD. Postsynaptic inhibition of primate spinothalamic neurons by stimulation in nucleus raphe magnus. Brain Res 1981;204:184-8
74. Jordan LM, Kenshalo DR, Martin RF, Haber LH, Willis WD. Depression of primate spinothalamic tract neurons by iontophoretic application of 5-hydroxytryptamine. Pain 1978;5:135-42
75. Schaible HG, Schmidt RF. Effects of an experimental arthritis on the sensory properties of fine articular afferent units. J Neurophysiol (Bethesda) 1985;54:1109-22
76. Schaible HG, Schmidt RF. Time course of mechanosensitivity changes in articular afferents during a developing experimental arthritis. J Neurophysiol (Bethesda) 1988;60:2180-94
77. Schaible HG, Grubb BD, Neugebauer V, Ottman M. The effects of NMDA antagonists on neuronal activity in cat spinal cord evoked acute inflammation in the knee joint. Eur J Neurosci 1991;3:981-91
78. Neugebauer V, Lucke T, Schaible HG. N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists block the hyperexcitability of dorsal horn neurons during development of acute arthritis in cat's knee joint. J Neurophysiol (Bethesda) 1993;70:1365-77
79. B receptor antagonist in rats. J Pharm Exp Ther 1994;271:76-82
80. Lee GY-P, Teyler TJ, Brown LM. The effects of valproic acid on PKC activity in the rat hippocampus. Abstract, 506.1 Society for Neuroscience Meeting Miami Beach Florida, Nov. 13-18, 1994
81. Worley PF, Baraban JM, Snyder SH. Heterogeneous localization of protein kinase C in rat brain: autoradiographic analysis of phorbol ester receptor binding. J Neurosci 1986;6:199-207
82. Mori M, Kose A, Tsujino T, Tanaka C. Immunocytochemical localization of protein kinase C subspecies in the rat spinal cord: light and electron microscopic study. J Comp Neurol 1990;229:167-77
83. Coderre TJ, Pitcher GM, Yashpal K. Pharmacological and anatomical evidence for a contribution of protein kinase C to persistent pain and hyperalgesia following tissue injury in rats. Abstracts: 7th World Congress on Pain. IASP Publications Seattle, 1993:223
84. Melzack R, Casey KL. Sensory, motivational and central control determinants of pain. A new conceptural model. In: Kenshalo D, editor. The Skin Senses. Springfield IL: Charles C. Thomas, 1968:423-39